Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant

David Jonathan Gottlieb1,2,3, Leighton Edward Clancy2,4, Barbara Withers1,3, Helen Marie McGuire5,6,7, Fabio Luciani8, Mandeep Singh8,10, Brendan Hughes8, Brian Gloss3, David Kliman2, Chun Kei Kris Ma2, Shyam Panicker2, David Bishop1,2,3, Ming-Celine Dubosq1,2,3, Ziduo Li3, Selmir Avdic1,3, Kenneth Micklethwaite1,2,3,4 & Emily Blyth1,2,3,4

1Sydney Medical School, University of Sydney, Sydney, NSW, Australia
2Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, NSW, Australia
3Westmead Institute for Medical Research at the University of Sydney, Westmead, NSW, Australia
4Sydney Cellular Therapies Laboratory, NSW Health Pathology ICPMR, Sydney, NSW, Australia
5Ramaciotti Facility for Human Systems Biology, The University of Sydney, Sydney, NSW, Australia
6Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
7Discipline of Pathology, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia
8Kirby Institute, University of New South Wales, Sydney, NSW, Australia
9The Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
10Faculty of Medicine, St. Vincent's Clinical School, UNSW, Sydney, NSW, Australia

Abstract

Objectives. Adoptive immunotherapy using donor-derived antigen-specific T-cells can prevent and treat infection after allogeneic haemopoietic stem cell transplant (HSCT). Methods. We treated 11 patients with a prophylactic infusion of 2 x 10^7 cells per square metre donor-derived T-cells targeting seven infections (six viral and one fungal) following HSCT. Targeted pathogens were cytomegalovirus (CMV), Epstein–Barr virus (EBV), adenovirus, varicella zoster virus, influenza, BK virus (BKV) and Aspergillus fumigatus. Results. T-cell products were successfully generated in all patients with 10 products responsive to 6 or 7 infections. T-cell infusions were associated with increases in antigen-experienced activated CD8^+ T-cells by day 30. CMV, EBV and BKV reactivation occurred in the majority of patients and was well controlled except where glucocorticoids were administered soon after T-cell infusion. Three patients in that circumstance developed CMV tissue infection. No patient required treatment for invasive fungal infection. The most common CMV and EBV TCR clonotypes in the infusion product became the most common clonotypes seen at day 30 post-T-cell infusion. Donors and their recipients were recruited to the study prior to transplant. Grade III/IV graft-versus-host disease developed in four patients. At a median follow-up of 390 days post-transplant, six patients had died, 5 of relapse, and 1 of multi-organ failure. Infection did not contribute to death in any patient. Conclusion. Rapid reconstitution of immunity to a broad range of viral and fungal infections can be achieved using a
INTRODUCTION

It has been almost 30 years since the first demonstration that T-cell immunity to cytomegalovirus (CMV) could be transferred from stem cell donor to recipient via the adoptive transfer of in vitro-generated donor-derived CMV-specific T-cells. Since then, many studies have shown that adoptive immunotherapy using antigen-specific T-cells can effectively treat uncontrolled Epstein-Barr virus (EBV) and CMV infections. A smaller number of studies have shown that virus-specific T-cells given prophylactically prevent or reduce the severity of post-transplant infections.

More recently, adoptive immunotherapy approaches have been extended to the therapy of other viruses including adenovirus, HHV6, BK virus (BKV), Varicella zoster virus (VZV) and Influenza A, all of which cause morbidity and mortality in immunosuppressed transplant recipients. Non-viral pathogens are also potential T-cell targets. Using lysates or extracts of common fungal pathogens, we and others have stimulated and expanded T-cells specific for yeasts and moulds.

Infection with multiple double stranded DNA viruses is common after allogeneic stem cell transplant (HSCT) and when it occurs is associated with an increased risk of death. T-cells with multiple infectious specificities can be used entirely prophylactically or to enhance immunity to a current infection while simultaneously providing prophylaxis against other infections. Trials of adoptive immunotherapy targeting combinations of CMV, EBV, adenovirus, BK virus and HHV6 and of CMV, EBV, adenovirus and VZV have been reported.

In the current trial, a T-cell product specific for CMV, EBV, adenovirus, VZV, BK virus, influenza and Aspergillus fumigatus was infused prophylactically. This is the first trial in which seven pathogens have been targeted as part of a prophylactic adoptive immunotherapy strategy and the first that includes a fungal pathogen as a target.

RESULTS

Participant characteristics

Patient characteristics are shown in Table 1. Twelve patients were recruited to the study from November 2013 to December 2015. One patient failed to return for post-transplant or trial follow-up visits and was not included in this analysis. Seven males and four females aged from 26 to 66 years (median 50) were included. All patients underwent transplant for malignant disease. Post-transplant GVHD prophylaxis was with ciclosporin and methotrexate in four cases (2 omitted day 11 methotrexate), ciclosporin and mycophenolate mofetil (MMF) in three cases and post-transplant cyclophosphamide, tacrolimus and MMF in the four haploidentical transplant recipients.

Characteristics of the T-cell products

T-cell product characteristics are shown in Figure 1. Mean fold expansion of cell number in culture was 6.8-fold (range 2.6–22.4) and post-thaw viability mean 82% (range 70–99; Figure 1a–c). Products were mainly CD3+ cells (mean 95%, range 89–99), CD4+ and CD8+ cells comprised a mean of 55% and 37% respectively. NK, monocyte and B cells means were 2.2%, 0.2% and 1.2% respectively; T-cells were mainly Tem (mean 75%) and T cm (mean 20%; Figure 1d). Antigen specificity measured by MHC tetramer (available for six epitopes in four cases) comprised 28% of CD8+ cells (range 2–79). The mean percentage of interferon (IFN)-γ producing CD3+ cells (all antigens) measured by intracellular cytokine staining was 23% (range 8–60). The proportion of antigen-specific cells that reacted to individual antigens is shown in Figure 1e. CMV-responsive cells comprised a mean of 39% of reactive T-cells in seropositive donors. Responses to EBV antigens displayed the most variability (mean for all EBV antigens 4%, three cases of no EBV-specific
response in seropositive donors). VZV and influenza comprised 16% and 30% respectively. Adenovirus, Aspergillus and BKV responses made up a median of 8%, 4% and 2% respectively (Figure 1e). Of 10 products in which antigen-specific response testing was available, six responded to all possible pathogens, four had one pathogen to which there was no response (EBV n = 3 and VZV n = 1; Figure 1f).

### Administration of T-cell product

Infusion day varied from day +28 to +76 post-transplant. Reasons for delay in T-cell infusion were active viral reaction with CMV, EBV and/or BKV (n = 4), severe mucositis and deconditioning (n = 1) and renal impairment (n = 1; Table 1). Two patients were receiving prednisone at doses under 0.5 mg kg⁻¹ daily at the time of T-cell infusion, both for acute graft-versus-host disease (GVHD) of the skin. In both patients, the dose of prednisone was being weaned at the time of infusion.

### Adverse events after administration of T-cell product

There were no acute infusion related adverse events. GVHD, relapse and death are shown in Table 1.

---

**Table 1. Participant characteristics**

| Patient | Age, (years) | Sex | Transplant indication | Conditioning HSCT, HLA match | T-cell depletion (in vivo) | GVHD prophylaxis | CMV serostatus R/D | EBV serostatus R/D | VZV serostatus R/D | Day of T-cell infusion | Reason for delay in T-cell infusion |
|---------|--------------|-----|-----------------------|------------------------------|--------------------------|------------------|-------------------|-------------------|-------------------|-----------------------|----------------------------------|
| 1       | 56           | F   | NK leukaemia relapsed post-ASCT | RIC, MMSD³ | ATG 30 mg | Cyc MMF | Pos/Pos | Pos/Pos | Pos/Pos | 76 | Active CMV, EBV, steroids, cardiomyopathy, skin GVHD |
| 2       | 60           | F   | CLL complex karyotype | RIC, MUD | ATG 30 mg | Cyc MTX¹ | Pos/Pos | Pos/Pos | Pos/Pos | 52 | Active CMV |
| 3       | 53           | M   | AML CR1 | RIC, MSD | ATG 15 mg | Cyc MMF | Pos/Neg | Pos/Pos | Pos/Pos | 31 | – |
| 4       | 45           | M   | AML CR1 | RIC, MAC, MSD | – | Cyc MTX² | Neg/Neg | Pos/Pos | Pos/Pos | 40 | – |
| 5       | 50           | M   | AML CR1 complex cytogenetics | MAC, MSD | – | Cyc MTX¹ | Pos/Pos | Pos/Pos | Pos/Pos | 37 | Renal impairment due to Cy toxicity |
| 6       | 44           | M   | EBV + NK lymphoma/HLH PR | RIC, haplo | – | PT Cy tacrolimus/MMF | Pos/Pos | Pos/Pos | Pos/Pos | 28 | – |
| 7       | 66           | F   | AML CR2 | RIC, haplo | – | PT Cy tacrolimus/MMF | Pos/Pos | Pos/Pos | Pos/Pos | 38 | Active CMV, BKV |
| 8       | 26           | M   | ALL CR3 | RIC, haplo⁵ | – | PT Cy tacrolimus/MMF | Pos/Neg | Pos/Neg | Neg/Pos | 59 | Active CMV, skin GVHD |
| 9       | 49           | M   | NHL mult relapse | RIC, haplo⁶ | – | PT Cy tacrolimus/MMF | Neg/Pos | Pos/Pos | Pos/Pos | 28 | – |
| 10      | 60           | F   | AML CR1 | RIC, MSD | – | Cyc MMF | Pos/Pos | Pos/Pos | Pos/Unk | 28 | – |
| 11      | 36           | M   | AL biphenotypic CR1 | RIC, MAC, MUD | ATG 20 mg | Cyc MMF | Pos/Pos | Pos/Pos | Pos/Unk | 32 | – |

ASCT, autologous stem cell transplant; ATG, antithymocyte globulin (rabbit, Fresenius); CycI, cyclosporine; MMF, mycophenolate mofetil; MMSD, mismatched sibling donor; MSD, matched sibling donor; MTX, methotrexate; PR, partial remission; PT Cy, post-transplant cyclophosphamide; RIC, reduced intensity conditioning; tacrolimus; unk, unknown.

¹ Beyond day 35 post-transplant.
² HLA-B1 antigen mismatch.
³ MTX 15 mg m⁻² D1, 10 mg m⁻² D3,6,11.
⁴ D11 MTX omitted due to mucositis.
⁵ 2nd allogeneic stem cell transplant.
⁶ MTX 10 mg m⁻² D1, 3, 6.
Figure 1. Characteristics of 11 multi-pathogen T-cell products at completion of expansion in vitro. (a) Total T-cell numbers in culture. (b) Fold expansion of cell number in culture. (c) Post-thaw viability as measured by flow cytometry. (d) Immunophenotype of final T-cell products (tetramer is % of CD8+ cells; see Supplementary table S3 for epitopes and HLA restriction). (e) Proportion of each product’s antigen-specific cells responding to each antigen (n = 10 products; values are after subtraction of negative control). (f) Responsiveness of individual products to each pathogen (n = 10 products). Blue blocks indicate response by cytokine flow cytometry for interferon gamma > 1%, yellow blocks < 1%, clear blocks donor seronegative for that pathogen; all values are after subtraction of negative control. Symbols refer to the same patient in all subfigures. * = donor CMV seronegative; ^ = donor EBV negative; Adv, adenovirus; ASP, aspergillus; BKV, BK virus; CMV, cytomegalovirus; EBV seronegative; EBV, Epstein–Barr virus; Flu, influenza; VZV, varicella zoster virus.
Table 2. In six cases, acute GVHD developed after T-cell infusion (median day post-transplant 71, range 36–109; median day post-infusion 33 days, range 8–71). In two additional cases (patient nos 1 and 8), acute skin GVHD developed prior to T-cell infusion but resolved sufficiently to allow T-cell infusion at a later date. Neither patient developed recurrent acute GVHD after T-cell infusion. Grades of acute GVHD in the six patients with acute GVHD after T-cell infusion were I (n = 1), II (n = 1), III (n = 2) and IV (n = 2). Grades I and II GVHD affected skin only while grade III/IV acute GVHD affected skin and gut in three cases and gut only in one case. All four patients with grade III/IV acute GVHD were at high risk of GVHD (omission of day 11 methotrexate (n = 2), early cessation of ciclosporin post-transplant due to renal impairment (n = 1) and use of reduced doses of ATG and post-transplant methotrexate (n = 1)). Three patients developed chronic GVHD by NIH consensus criteria, mild in one case and moderate in two cases.

### Survival

After a median follow-up period of 390 days, 6 of the 11 patients recruited to the study died (day post-transplant 138–743; Table 2). Of these, five died from recurrence of the malignant disease for which their transplant was performed. One patient (patient no. 9) who underwent transplant after multiple courses of chemotherapy for non-Hodgkin lymphoma which was not in remission at the time of transplant died of multi-organ failure 138 days post-transplant.

### Immune reconstitution

#### T-cell recovery

The majority of patients receiving multi-pathogen T-cells showed an increase in peripheral blood T-cell numbers within 30 days of infusion. This increase consisted predominantly of antigen-experienced activated effector memory CD8+ T-cells expressing CD27, CD45RO, CD62L, CD38, CD57 and CD45RA (Figure 2a).

#### ELISPOT analysis

ELISPOT analysis was used to determine interferon-γ release from lymphocytes following stimulation with individual pathogens (Figure 2b). CMV responses were dominant and increased in all cases. For other pathogens, there was a small increase in IFN-γ response in the majority of cases, with occasional patients showing a substantial increase after infusion (EBV n = 1, BKV n = 1, VZV n = 1, aspergillus n = 1).
Effect of corticosteroid administration on lymphocyte number and phenotype

Nine patients commenced corticosteroid treatment after transplant, in all but one case for acute GVHD. Patient 9 developed a maculopapular rash on day 35 post-transplant, 7 days after T-cell infusion, which was treated with prednisone for presumed GVHD. Skin biopsy showed findings consistent with a drug rash and prednisone was rapidly weaned. Absolute lymphocyte counts fell from a mean of \(0.9 \times 10^9\) L\(^{-1}\) (range 0.1–2.6) to 0.2 (range 0.0–0.6) at a mean of 11 days after commencing corticosteroids \((P = 0.035;\) Supplementary figure 1). To determine the effect of corticosteroids on antigen-specific T-cells, a detailed analysis was performed of a representative case (patient 10;
Figure 3. Effect of corticosteroids on immune reconstitution. (a) Time course of clinical events in patient 10 including staining with HLA-A*02:01 NLVPMVATV and HLA-B*07:01 TPRVTGGGAM tetramer in CD8^+ cells in peripheral blood pre- and post-T-cell infusion. (b) ViSNE of mass cytometry phenotype in peripheral blood in patient 10 pre-T-cell infusion, at day 31 post-infusion and at day 94 post-infusion. Upper panel shows major cell subsets. Increase, particularly in CD8^+ cell numbers, is shown at D31 post-infusion (intensity of red segment is proportional to cell number) with reduction at D93 post-infusion. Lower panel shows presence of the specific marker indicated within each subset. Cell-specific areas are as for upper panel but colour in each area refers to cell number on scale shown at right.
Figure 3a). This patient developed low level CMV viraemia at day 34 post-transplant, 6 days after multi-pathogen T-cell infusion. This was followed by expansion of NLVPMVATV (HLA A*0201) and TPRVTGGGAM (HLA B*0701) tetramer positive populations that constituted over 10% of CD8+ cells within 30 days of T-cell infusion leading to control of viral reactivation without antiviral therapy. After corticosteroids were administered for GVHD at post-transplant day 73 (D38 post-T-cell infusion), there was regression of total CD4+ and CD8+ cells, especially CD8+ T-cells expressing CD27, CD45RO, CD62L, CD38, CD57 and CD45RA and tetramer positive CD8+ T-cells (Figure 3b).

### Viral reactivation

#### CMV

Eight of ten patients had their initial reactivation of CMV prior to or on the day of T-cell infusion (Table 3, Figure 4). In six patients (nos 3, 5, 7, 9, 10 and 11), peak post-transplant CMV copy number was observed after T-cell infusion (Figure 4b). All five patients with a maximum viral titre above 1000 IU mL⁻¹ reactivated CMV after commencement of corticosteroids given for suspected or proven graft-versus-host disease (GVHD). Three patients (nos 3, 5 and 9) developed CMV colitis; the interval between T-cell infusion and steroid initiation in these patients was 4, 38 and 10 days and the patients received maximal steroid doses of 2, 2 and 0.75 mg per kg per day prednisone respectively. Patient 3 had received a T-cell product from a CMV seronegative donor and the product had no CMV specificity. He was eventually successfully salvaged with third-party CMV-specific T-cells on another trial.

### EBV

EBV viraemia occurred in seven patients (Table 4). In six patients (patient nos 3, 4, 5, 6, 10 and 11) maximum EBV copy number occurred after T-cell infusion (Figure 5). Patient 6 underwent transplant for EBV associated lymphoma. Although EBV viraemia disappeared post-transplant and T-cell infusion, it subsequently recurred and was found to be associated with disease relapse. The patient was censored from the trial at the time of relapse. In the remaining five cases, EBV viraemia developed after commencement of corticosteroids. EBV viraemia exceeded 5000 copies per mL in only one case and none of the patients received treatment for viraemia. One patient (no. 1) was treated with...
Figure 4. CMV infection. (a) Patients 1, 2, 6 and 8 with maximum CMV copy number prior to or at the time of T-cell infusion. (b) Patients 3, 5, 7, 9, 10 and 11 with maximum copy number after T-cell infusion. (c) Patient 4 with no CMV reactivation at any time. x-axis days post-transplant, left y-axis CMV DNA copies mL$^{-1}$, right y-axis corticosteroid dose (equivalent to prednisone dose in mg kg$^{-1}$; grey blocks). The vertical dashed line shows T-cell infusion. Shading indicates censor due to study withdrawal or relapse of original disease.
two doses of rituximab, the first given prior to and the second after T-cell infusion. No further therapy was given. No cases of PTLD occurred.

**Adenovirus**

None of the 11 patients had adenovirus detected in blood or tissues at any time following transplant.

**Influenza**

Two patients (patient nos 5 and 6) had influenza A detected on nasopharyngeal swabs, one prior to and one 37 days after T-cell infusion. The former was treated with oseltamivir orally for 10 days with symptom resolution, the latter was not treated and symptoms resolved.

**Varicella zoster virus**

There were no cases of herpes zoster, and varicella zoster was not detected by laboratory testing in any patient.

**BK virus**

BK viruria was detected in 10 of 11 patients (Table 5, Figure 6) most commonly prior to or at the time of T-cell infusion (Figure 6a). BK viruria was controlled rapidly after T-cell infusion in all patients. In four patients BK virus developed only after T-cell infusion, in all cases in association with corticosteroid and/or other GVHD treatment (Figure 6b). BK virus infection was short lived in all cases although one patient (patient no. 4) developed brief symptomatic grade 2 haemorrhagic cystitis.

**Aspergillus**

Four patients had positive peripheral blood Aspergillus PCR post-transplant. In two cases positive tests occurred prior to T-cell infusion. Two patients had a single positive peripheral blood Aspergillus PCR after T-cell infusion but neither of them nor any other patient required systemic antifungal treatment for a proven or probable invasive fungal infection post-transplant.

**Clone tracking**

To determine the fate of individual T-cell clones, TCR sequences identified in patient 10 prior to infusion and in the infused T-cell product were tracked up to day 278 post-infusion. Public CMV-specific clonotypes (cross referenced with the VDJ database vjd.db.CDR3.net) expanded in the patient
Figure 5. EBV infection. (a) Patients 1 and 6 with EBV detected prior to or at the time of T-cell infusion. Patient 6 had EBV viraemia associated with relapse of EBV driven lymphoma. (b) Patients 3, 4, 5, 10 and 11 with EBV detected after T-cell infusion. (c) Patients 2, 7, 8 and 9 with no EBV reactivation at any time. x-axis days post-transplant, left y-axis EBV DNA copies mL⁻¹, right y-axis corticosteroid dose (equivalent to prednisone dose in mg kg⁻¹; grey blocks). The vertical dashed line shows T-cell infusion. Shading indicates censor due to study withdrawal or relapse of original disease. The downward blue arrow indicates rituximab administration.
by day 30 post-infusion during CMV viraemia and contracted thereafter (Supplementary figure 2a). Public EBV-specific clonotype proportions were smaller than CMV in all samples but also expanded maximally at the day 30 time point in the absence of detectable EBV viraemia (Supplementary figure 2a). In both cases, the dominant clones were present in both the infusion product and the pre-infusion sample. TCR clones shared with the day 278 sample were plotted to assess when the long-term clones became established in patient 10. The day 94 and day 278 had a larger number of shared clones than other samples and the Morisita similarity index (comparing each time point with the final one on D278) rose over time indicating that in this patient the long-term clonality was largely established by day 94 (Supplementary figure 2b and c).

**DISCUSSION**

We manufactured and prophylactically administered donor-derived T-cells specific for seven infectious pathogens that cause clinical disease in allogeneic stem cell transplant recipients. Generation of the multi-pathogen T-cell product was feasible and there were no acute infusion related toxicities. We observed acute GVHD including moderate and severe grades in patients that received T-cell infusions and we cannot exclude the possibility that the T-cell infusions contributed to the development of acute GVHD in these patients. However GVHD is a risk in all allogeneic stem cell transplant recipients and in this study we administered antigen-specific T-cells at a median of 37 days post-transplant and in this study we administered antigen-specific T-cells at a median of 37 days post-transplant.

**Table 5. BKV reactivation**

| Patient | BKV reactivation | Timing of BKV reactivation in relation to T-cell infusion | BKV reactivation free interval post-transplant (days) | Day of T-cell infusion | BKV at T-cell infusion (copies ml⁻¹) | BKV reactivation free interval post-T-cell infusion (days)* | Corticosteroid administration post-transplant (Y/N); day post-transplant started, max dose (mg kg⁻¹) | Peak BKV copy number pre; post-T-cell infusion (copies ml⁻¹) | Days to maximum copy number post-T-cells | BKV disease symptomatic |
|---------|------------------|------------------------------------------------------|-----------------------------------------------|----------------------|--------------------------------------|--------------------------------------------------------|---------------------------------------------------------------|-----------------------------------------------|-------------------------------|---------------------|
| 1       | Y                | Pre, at and post                                       | 21                                            | 76                   | 1.5 x 10⁹                           | 0                                                     | Y; 26; 0.5                                              | 1.5 x 10⁶                                             | 4                             | N                   |
| 2       | Y                | Pre, at and post                                       | 38                                            | 52                   | 9.9 x 10⁹                           | 21                                                    | Y; 35; 2                                                | 9.9 x 10⁶                                             | 7                             | N                   |
| 3       | Y                | Pre, at and post                                       | 24                                            | 31                   | 2.9 x 10⁹                           | 21                                                    | Y; 81; 2                                                | 8.4 x 10⁹                                             | 63                            | Y                   |
| 4       | Y                | Post                                                 | 86                                            | 40                   | NT                                  | 0                                                     | Y; 75; 2                                                | 0                                                       | –                             | N                   |
| 5       | N                | –                                                    | 28                                            | 28                   | > 10 x 10¹⁰                         | 0                                                     | N                                                      | > 10 x 10¹⁰                                           | 17                            | N                   |
| 6       | Y                | At and post                                           | 31                                            | 38                   | 1.6 x 10¹⁰                         | 0                                                     | Y; 116; 0                                               | 8.7 x 10⁹                                             | 14                            | N                   |
| 7       | Y                | Pre, at and post                                       | 52                                            | 59                   | NT                                  | 3                                                     | Y; 17; 0.5                                              | 3.1 x 10¹⁰                                            | 3                             | N                   |
| 9       | N                | –                                                    | 28                                            | 28                   | NT                                  | 3                                                     | Y; 38; 0.5                                              | 1.7 x 10¹⁰                                            | –                             | N                   |
| 10      | Y                | Post                                                 | 34                                            | 28                   | NT                                  | 6                                                     | Y; 73; 2                                                | 4.6 x 10⁹                                             | 81                            | N                   |
| 11      | N                | –                                                    | 32                                            | 32                   | –                                    | –                                                     | –                                                      | –                                                             | –                             | N                   |

NT, not tested; –, BK virus was not detected in blood on at least 1 occasion. 
*BKV reactivation free interval was considered to be zero if BKV was detectable in the urine on the day of the T-cell infusion and on the following test.
Figure 6. BKV infection. (a) Patients 1, 2, 3, 6, 7 and 8 with BKV in urine prior to, at and after T-cell infusion. (b) Patients 4, 5, 10 and 11 with BKV in urine at and after T-cell infusion. (c) Patient 9 without BKV in urine at any time. x-axis days post-transplant, left x-axis copies BKV DNA copies mL$^{-1}$ in urine (red) and blood (blue), right y-axis corticosteroid dose (equivalent to prednisone dose in mg kg$^{-1}$; grey blocks). Shading indicates censor due to study withdrawal or relapse of original disease. Inverted diamond shows episode of haemorrhagic cystitis.
GVHD at our centre was 35% with 18% suffering grade III/IV disease. The confidence interval of GVHD incidence is wide given the small numbers in this study and it is therefore conceivable that the GVHD we observed was consistent with our previous experience and the risk factors involved.24,25 Of note, previous studies of donor-derived pathogen-specific T-cells that showed low GVHD rates recruited patients receiving transplant regimens associated with significantly lower rates of GVHD26,27 and enrolled patients in whom GVHD had not developed after transplant thus selecting a particularly low risk cohort. In contrast, our patients were enrolled prior to transplant and received conditioning regimens without CD34+ cell selection, constituting a more typical group of transplant recipients.

Only one previous study has targeted fungi with adoptive T-cell immunotherapy and it did not administer fungal T-cells prophylactically.19 Previously, T-cells recognising five viral pathogens (CMV, EBV, adenovirus, HHV6 and BK virus) have been simultaneously targeted by adoptive immunotherapy.11 Our data extend the range of viral pathogens targeted and add fungal infections as a target for adoptive immunotherapeutic approaches. Despite the presence of GVHD and the use of intermediate to high dose corticosteroids, we observed only 1 non-relapse death in the 11 patients reported here. A twelfth patient whose information was not included due to refusal to attend for regular follow-up also remains alive. No patient died of infection. However, we observed three cases of CMV colitis, all following administration of high doses of corticosteroids after T-cell infusion; one of these had a CMV seronegative donor from whom no CMV-specific T-cells were expanded. This patient was salvaged with third-party CMV-specific T-cells on another trial. A notable feature of the three patients who developed CMV colitis was the short interval between T-cell infusion and corticosteroid administration. Three other patients who received similar doses of corticosteroids but starting later after T-cell infusion (including one who received second line therapy for GVHD) required no or relatively brief anti-CMV treatment. In five patients EBV was detected only after T-cell infusion, a finding that may represent shedding from cells destroyed as part of an immune attack on EBV infected tissues.28 In all five patients (including one patient who reactivated EBV while receiving corticosteroids, ATG and etanercept), EBV resolved without specific treatment. Similarly, although 10 of the 11 patients had BK virus identified in urine after transplant, there was only one brief episode of clinical haemorrhagic cystitis despite high viral copy numbers in some patients. Finally despite the use of intermediate to high dose corticosteroids and second line aGVHD treatment, no patient developed a systemic fungal infection or required escalation of standard antifungal prophylaxis.

Administration of the T-cell product was followed by an increase in peripheral blood T-cell numbers 30 days after infusion. The increase comprised principally activated antigen-experienced CD8+ T-cells. Detailed analysis of one patient using CyTOF showed rapid reconstitution of CMV immunity but clearly demonstrated the susceptibility of these cells to corticosteroids. There was little change in the number of CD4+ T-cells, regulatory T-cells or B cells after T-cell infusion. Our data do not allow us to identify the origin of the expanded CD8+ T-cells as the stem cell donor was the source of both the original stem cell infusion and the T-cell product. However in one patient, the most common CMV and EBV public clones at day 30 after infusion were also the most common in the T-cell product. Nine months after infusion, these clones had substantially contracted. T-cell infusion was followed by evidence of improved functional immunity only to CMV. We previously observed that prophylactic infusions of antigen-specific T-cells do not induce increases in detectable peripheral blood immunity in the absence of antigenemia.9 Consistent with this observation, enhanced CMV ELISPOT responses were numerically greatest in those who developed CMV viraemia. Only sporadic improvement in immune reconstitution to other infections was observed.

Our study has several limitations, and the data should be interpreted with caution. Most importantly, only a small number of patients with different diagnoses and undergoing various forms of transplant received the cellular therapy in this early phase trial. There was no comparator cohort, rendering it very difficult to draw conclusions about efficacy and potential adverse effects. Nevertheless, our data support the feasibility of ex vivo manufacture of T-cells targeting multiple opportunistic pathogens although they sound a note of caution regarding the risk of graft versus host associated with infusion of cells targeting multiple infectious antigens soon after allogeneic
stem cell transplant. Further prophylactic use of antigen-specific T-cell immunotherapy should only be combined with GVHD prevention methods such as CD34+ selection or other strategies such as TCRαβ T-cell, alloreactive or naïve T-cell depletion and should be cautious in the cell numbers used, the range of pathogens targeted and the need to monitor for GVHD risk.29,31 We recently commenced a pilot trial in which transplantation of in vitro isolated CD34+ stem cells will be followed by administration of limited numbers of narrowly targeted infection- and tumor-specific T-cells (ACTRN12618001090202) and have seen no GVHD in the first two patients treated using this approach. If similar results are replicated during pilot trial recruitment, we will move to establishment of a formal phase 1/2 study examining the safety and efficacy of this approach in allogeneic transplantation.

METHODS

Study design and participants

The study was conducted as a single-arm, open label phase I trial. Allogeneic HSCT recipients and their donors were recruited prior to transplant. Detailed inclusion and exclusion criteria are provided in Supplementary table 1. Written informed consent was obtained in accordance with the Declaration of Helsinki. The study was approved by the Western Sydney Local Health District Human Research Ethics Committee. This study was registered on the Australian and New Zealand Clinical Trial Registry as trial NCT02843321.

Generation of multi-pathogen T-cell product

The granulocyte colony-stimulating factor (G-CSF) primed apheresis product from each patient’s stem cell donor was used as the starting material for ex vivo T-cell expansion as previously described.9,32 Monocyte derived dendritic cells (moDCs) were pulsed with overlapping MACS GMP PepTivators for HCMV pp65, Adv5 Hexon, EBV BZLF1/LMP2A/EBNA-1 (Miltenyi Biotech, Bergisch Gladbach, Germany), peptide pools (15mers overlapping by 11 peptides) for BKV proteins LTA and VP1, or with varicella zoster vaccine, influenza vaccine (CSL, Melbourne, VIC, Australia) or lysate of Aspergillus fumigatus (Miltenyi Biotech). Irradiated pulsed moDCs were co-cultured with the monocyte-depleted fraction of G-CSF primed apheresis products isolated by Ficoll-Paque (GE Healthcare, Chicago, IL, USA) gradient centrifugation. After 7 days, cultures from individually stimulated products were combined and restimulated with peptide/lysate-pulsed moDCs. Cultures were continued for up to 21 days, with the addition of 20 U mL−1 interleukin-2, increasing to 50 U mL−1 from day 14 to 21. T-cell products were cryopreserved for later administration.

Assessment of T-cell product

Cell dose was based on post-thaw viability. Standard pathogen-specific T-cell product release criteria were applied as described previously9 and in Supplementary table 2. Flow cytometry for product release was performed using monoclonal antibodies directed against CD3, CD4, CD8, CD14, CD19 and CD56 (BD Biosciences, San Jose, CA, USA). Viability was assessed using 7-amino-actinomycin D (BD Biosciences) or hydroxystilbamidine (Life Technologies, Carlsbad, CA, USA). Viral antigen specificity and HLA-restricted epitope recognition were assessed using phycoerythrin-conjugated virus-specific iTagMHC class I human tetramers (Beckman Coulter, Brea, CA, USA; epitopes and HLA restriction are shown in Supplementary table 3) and by intracellular cytokine flow cytometry (IFC) after T-cell stimulation as previously described33 using the same antigens used for product manufacture (a representative example of IFC is shown in Supplementary figure 3). T-cell subsets were assessed using monoclonal antibodies directed against CD3, CD4, CD8, CD95, CD45RA, CD62L and Zombie (BD Biosciences) and defined as naïve (CD45RA−CD62L−), stem cell memory (Tscm) CD45RA−CD62L−CD95−, terminally differentiated effector (Tem) CD45RA−CD62L−, effector memory (Tem) CD45RA−CD62L+ and central memory (Tcm) CD45RA−CD62L+. Flow cytometry data were acquired on a FACSCanto II or LSRFortessa (BD Biosciences) and analysed with FlowJo software (version 10.0.8r1; Tree Star, Inc., Ashland, OR, USA).

Participant treatment and monitoring

Recipients were treated with a single infusion of 2 × 107 T-cells per square metre of body surface area on or after day 28 post-transplant as infection prophylaxis. Antiviral and antifungal monitoring included weekly CMV and EBV monitoring by PCR in all cases. Testing for other infections was performed at the discretion of treating clinicians based on patient symptoms. Initiation of treatment, choice of anti-infective agent, dose and duration of therapy were according to standard institutional practice. Patients were monitored for 12 months from the final infusion of T-cells for evidence of infections, toxicity, and immune cell recovery.

Outcomes

The primary end point of the trial was safety of the T-cell infusion. Secondary endpoints included post-infusion immune reconstitution, incidence of targeted infections and incidence of acute and chronic GVHD. All adverse events were graded according to the National Cancer Institute’s common terminology criteria for adverse events, version 4.03. Viral copy number was measured by quantitative PCR using the Roche-Cobas system (Hoffman La Roche, Germany). GVHD was graded according to standard criteria for acute and chronic GVHD.34,35

Immunological monitoring

Enzyme-linked immunospot assay (ELISPOT) was performed on post-infusion peripheral blood samples as previously
described\textsuperscript{23} using the same antigens as manufacturing and ICS assays. Mass cytometry was used to describe global immune recovery in some patients pre-infusion, day 30 and day 90 post-infusion. A panel of 2 fluorescent-tagged and 38 metal-tagged monoclonal antibodies was used (antibodies and corresponding metal tag in Supplementary Table 4). All pre-conjugated antibodies were purchased from Fluidigm, Toronto, Canada. All other antibodies were purchased in a carrier-protein-free format and conjugated with the metal isotope using the MaxPAR antibody conjugation kit (Fluidigm) according to the recommended protocol. Cells were acquired at a rate of 200–400 cells per second using a CyTOF 2 Helios upgraded mass cytometer (Fluidigm). Populations were gated manually and number of cells \(10^9\) \(L^{-1}\) calculated using lymphocyte and monocyte counts generated by the full blood count analyser on the day of sample collection (dual platform) as previously described.\textsuperscript{33}

**TCR sequencing**

TCR sequence acquisition was performed as previously described.\textsuperscript{36} RNA was isolated using Qiagen RNeasy Mini kits according to the manufacturer’s instructions. (Quantitect RT, QIAgen, Chadstone, VIC, Australia). Using 5 \(\mu\)L of cDNA template per reaction, TCR\(\gamma\) transcripts were PCR amplified from the ex vivo expanded T-cell product and post-infusion sorted PBMC samples using high-fidelity Q5 polymerase (NEB) and a mix of 19 Trbv-specific forward primers and a single Trbc-specific reverse primer. Forward and reverse primers had distinct 5’ overhang adapter sequences that enabled addition of sample-specific indices and P5/P7 sequencing adapters in a second PCR using the Illumina Nextera XT DNA library preparation kit. Before the second PCR, magnetic beads (Agencourt AMPure XP, Beckman Coulter) were used to enrich amplicons > 100 bp. Equimolar amounts of amplicons were pooled into a single tube, concentrated using magnetic beads and 300–500 bp amplicons were gel-purified before sequencing on an Illumina NextSeq machine, with a short read 1 of 6 bases followed by a read 2 of 145 bases. For TCR sequence processing, see the Supplementary Methods.

**Statistical analysis**

Demographics, clinical characteristics, viral reactivation, transplantation outcomes and immunological observations were tabulated for presentation or visualised with Prism v8.4.2 for Mac (GraphPad Software Inc., La Jolla, CA, USA). The paired t-test was used to compare means. Mass cytometry analysis was analysed using FlowJo X 10.0.7r2 software (FlowJo, LLC, Ashland). The visualised t-distributed stochastic neighbourhood embedding (t-SNE) algorithm (implemented in FlowJo as a plugin) was utilised to perform dimensionality reduction and visualisation of immune subsets across samples.

**ACKNOWLEDGMENTS**

We acknowledge Nancy Kim for assistance with pharmacy and Renee Simms, Janine Street and Jane Burgess for technical support. This work was supported by grants from the National Health and Medical Research Council of Australia, the Leukaemia Foundation, Cancer Council NSW, NSW Cancer Institute and the University of Sydney.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**AUTHOR CONTRIBUTIONS**

David Gottlieb: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Visualization; Writing-original draft; Writing-review & editing. Leighton Clancy: Conceptualization; Formal analysis; Methodology; Supervision; Writing-review & editing. Barbara P Withers: Investigation; Methodology; Visualization; Writing-review & editing. Helen McGuire: Investigation; Supervision; Visualization; Writing-review & editing. Fabio Luciani: Formal analysis; Software; Visualization; Writing-review & editing. Mandeep Singh: Methodology; Software; Writing-review & editing. Brendan Hughes: Formal analysis; Validation; Visualization. Chun-Kei-Kris Ma: Methodology; Project administration; Writing-review & editing. Shyam Panicker: Investigation; Project administration; Writing-review & editing. Brian Gloss: Formal analysis; Validation; Visualization. David Kliman: Investigation; Project administration; Writing-review & editing. Kenneth Micklethwaite: Conceptualization; Investigation; Methodology; Project administration; Writing-review & editing. Emily Blyth: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Visualization; Writing-original draft; Writing-review & editing.

**REFERENCES**

1. Greenberg PD, Reusser P, Goodrich JM, Riddell SR. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro. Ann N Y Acad Sci 1991; 636: 186–195.
2. Peggs K, Verfuether S, Pizzy A et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375–1377.
3. Heslop HE, Ng CY, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551–555.
4. Lucas KG, Szalzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004; 100: 1892–1901.
5. Feuchtinger T, Lang P, Hamprecht K et al. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-γ secretion for adoptive immunotherapy. Exp Hematol 2004; 32: 282–289.

6. Einsele H, Roosnek E, Rufer N et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916–3922.

7. Feuchtinger T, Opher K, Bethge WA et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116: 4360–4367.

8. Micklethwaite K, Hansen A, Foster A et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 707–714.

9. Blyth E, Clancy L, Simms R et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013; 121: 3745–3758.

10. Leen AM, Myers GD, Bollard CM et al. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci 2005; 1062: 104–115.

11. Papadopoulou A, Gerdemann U, Katari UL et al. Activity of broad-spectrum T cells as treatment for Adv, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014; 6: 242ra283.

12. Blyth E, Clancy L, Simms R et al. BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses. Transplantation 2011; 92: 1077–1084.

13. Blyth E, Gaundar SS, Clancy L et al. Clinical-grade varicella zoster virus-specific T cells produced for adoptive immunotherapy in hematopoietic stem cell transplant recipients. Cytotherapy 2012; 14: 724–732.

14. Gaundar SS, Blyth E, Clancy L, Simms RM, Ma CK, Gottlieb DJ. In vitro generation of influenza-specific polyfunctional CD4+ T cells suitable for adoptive immunotherapy. Cytotherapy 2012; 14: 182–193.

15. Gerdemann U, Keukens L, Keirnan JM et al. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood 2013; 121: 207–218.

16. Deo SS, Gottlieb DJ. Adoptive T-cell therapy for fungal infections in haematology patients. Clin Transl Immunol 2015; 4: e40.

17. Deo SS, Virassamy B, Halliday C et al. Stimulation with lysates of Aspergillus terreus, Candida krusei and Rhizopus oryzae maximizes cross-reactivity of anti-fungal T cells. Cytotherapy 2016; 18: 65–79.

18. Gaundar SS, Clancy L, Blyth E, Meyer W, Gottlieb DJ. Robust polyfunctional T-helper 1 responses to multiple fungal antigens from a cell population generated using an environmental strain of Aspergillus fumigatus. Cytotherapy 2012; 14: 1119–1130.

19. Perruccio K, Tosti A, Burchielli E et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397–4406.

20. Tramsen L, Koehl U, Tonn T et al. Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplant 2009; 43: 13–19.

21. Tramsen L, Schmidt S, Boenig H et al. Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes. Cytotherapy 2013; 15: 344–351.

22. Hill JA, Mayer BT, Xie H et al. The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood 2017; 129: 2316–2325.

23. Ma CK, Blyth E, Clancy L et al. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation. Cytotherapy 2015; 17: 1406–1420.

24. Bilmon IA, Wkan J, Gottlieb D et al. Haploidentical bone marrow transplants for haematological malignancies using non-myeloablative conditioning therapy and post-transplant immunosuppression with cyclophosphamide: results from a single Australian centre. Internal Med J 2013; 43: 191–196.

25. Bradstock K, Bilmon I, Wkan J et al. Influence of stem cell source on outcomes of allogeneic reduced-intensity conditioning therapy transplants using haploidentical related donors. Biol Blood Marrow Transplant 2015; 21: 1641–1645.

26. Leen AM, Myers GD, Sili U et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160–1166.

27. Gerdemann U, Katari UL, Papadopoulou A et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplantation. Mol Ther 2013; 21: 2113–2121.

28. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659–1665.

29. Mielke S, Nunes R, Rezvani K et al. A clinical-scale selective allelodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 2008; 111: 4392–4402.

30. Bleakley M, Heimfeld S, Loeb KR et al. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest 2015; 125: 2677–2689.

31. Montoro J, Cebiero I, Hilden P et al. Ex vivo T cell-depleted hematopoietic stem cell transplantation for adult patients with acute myelogenous leukemia in first and second remission: long-term disease-free survival with a significantly reduced risk of graft-versus-host disease. Biol Blood Marrow Transplant 2020; 26: 323–332.

32. Clancy L, Blyth E, Simms R et al. CMV-specific cytotoxic T lymphocytes can be efficiently expanded from G-CSF mobilised haematopoetic progenitor cell products ex vivo and safely transferred to stem cell transplant recipients to facilitate immune reconstitution. Biol Blood Marrow Transplant 2013; 19: 725–734.

© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc.
33. McGuire HM, Rizzetto S, Withers BP et al. Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV-specific T cells. *Clin Transl Immunol* 2020; 9: e1149.

34. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. *Transplantation* 1974; 18: 295–304.

35. Jagasia MH, Greinix HT, Arora M et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. *Biol Blood Marrow Transplant* 2015; 21: 389–401 e381.

36. Wirasinha RC, Singh M, Archer SK et al. γδ T-cell receptors with a central CDR3 cysteine are enriched in CD8α intraepithelial lymphocytes and their thymic precursors. *Immunol Cell Biol* 2018; 96: 553–561.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.